Google
ADXN — ADDEX THERAPEUTICS LTD (Healthcare >> Biotechnology)
ADXN FAQ
What is ADXN's ROE?
ADDEX THERAPEUTICS LTD reports a Return on Equity (ROE) of -158.46%.
What is ADXN's dividend yield?
ADDEX THERAPEUTICS LTD offers a dividend yield of 0.00%.
What is ADXN's Deepscope Quality Score?
Deepscope rates ADXN's overall financial quality at 0 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ADXN?
Deepscope's AI Timing Score for ADXN is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ADXN belong to?
ADDEX THERAPEUTICS LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 6.20
Price
-0.30
(-4.62%)
Day Change
|
|
|---|
ADXN, the overall quality is not good ( Quality = 0) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.20 |
| PBV / Sector |
1.73 / 4.79
|
| Earning Per Share | -5.69 |
| PE / Sector |
N/A / 18.05
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
0.01 M
GREAT
|
| Average 1W Daily Value |
0.02 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-12 09:43:13 |
| Symbol | ADXN |
| Name | ADDEX THERAPEUTICS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.23 / 9,010.81 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Chemin des Mines, 9, Geneva, Switzerland, 1202
Phone: 41 22 884 1555
Website: https://www.addextherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
